IFN-beta Protein, Human, Recombinant

• Background:

  Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites, and tumor cells. Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS) . Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation.

• Synonyms:

  IFB Protein, Human; IFF Protein, Human; IFN-beta Protein, Human; IFNB Protein, Human; Interferon beta Protein, Human

• Gene Name:

  Interferon, beta 1, fibroblast

• UniProt:

  P01574

• Expression System:

  CHO Stable Cells

• Tag:

  No tag

• Endotoxin:

  < 1.0 EU per μg of the protein as determined by the LAL method.

• Purity:

  > 95 % as determined by SDS-PAGE.

• Activity:

  Measured in antiviral assays using WISH cells infected with vesicular stomatitis virus. The EDfor this effect is typically 2-20 pg/mL.

• Form:

  Lyophilized

• Buffer:

  Lyophilized from sterile 10mM NaAC, 40mM Arg, 0.12mg/ml Met, 146mg/ml Sucrose, 0.1% PF-68, pH 4.5 Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.

• Function:

  Immunotherapy proteins, Cytokine Proteins, Growth Factor proteins, Biological Target proteins

• Molecular Weight:

  The recombinant human IFNβ consists of 166 amino acids and predicts a molecular mass of 20 KDa. It migrates as an approximately 20-23 KDa band in SDS-PAGE under reducing conditions.

• Storage Conditions:

  In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. Stable for 1 year at -20°C or below from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and opening the cap. For long-term storage, aliquot and store at -20°C or below. Avoid repeated freeze-thaw cycles.

• Symbol:

  IFNB1

• Species:

  Human

• Overview:

  A DNA sequence encoding the human IFNβ (P01574) (Met1-Asn187) was expressed.

• Uniprot URL:

  https://www.uniprot.org/uniprot/P01574

• AA Sequence:

  Met1-Asn187